CN103561727B - 每日给药1次的拉科酰胺制剂 - Google Patents
每日给药1次的拉科酰胺制剂 Download PDFInfo
- Publication number
- CN103561727B CN103561727B CN201180057820.9A CN201180057820A CN103561727B CN 103561727 B CN103561727 B CN 103561727B CN 201180057820 A CN201180057820 A CN 201180057820A CN 103561727 B CN103561727 B CN 103561727B
- Authority
- CN
- China
- Prior art keywords
- lacosamide
- scheme
- preparation
- weight
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41915310P | 2010-12-02 | 2010-12-02 | |
US41915810P | 2010-12-02 | 2010-12-02 | |
EP10193561.7 | 2010-12-02 | ||
EP10193561A EP2468261A1 (en) | 2010-12-02 | 2010-12-02 | Formulation of lacosamide |
EP10193559.1 | 2010-12-02 | ||
EP10193559 | 2010-12-02 | ||
US61/419,158 | 2010-12-02 | ||
US61/419,153 | 2010-12-02 | ||
US201161444447P | 2011-02-18 | 2011-02-18 | |
US201161444439P | 2011-02-18 | 2011-02-18 | |
US61/444,447 | 2011-02-18 | ||
US61/444,439 | 2011-02-18 | ||
US201161485361P | 2011-05-12 | 2011-05-12 | |
US201161485354P | 2011-05-12 | 2011-05-12 | |
US61/485,354 | 2011-05-12 | ||
US61/485,361 | 2011-05-12 | ||
PCT/EP2011/006027 WO2012072256A2 (en) | 2010-12-02 | 2011-12-01 | Once daily formulation of lacosamide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103561727A CN103561727A (zh) | 2014-02-05 |
CN103561727B true CN103561727B (zh) | 2018-03-27 |
Family
ID=46172318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180057820.9A Expired - Fee Related CN103561727B (zh) | 2010-12-02 | 2011-12-01 | 每日给药1次的拉科酰胺制剂 |
Country Status (14)
Country | Link |
---|---|
US (4) | US20130251813A1 (pt-pt) |
EP (3) | EP2645997B1 (pt-pt) |
JP (2) | JP6027539B2 (pt-pt) |
KR (1) | KR101980386B1 (pt-pt) |
CN (1) | CN103561727B (pt-pt) |
AU (1) | AU2011335415B2 (pt-pt) |
BR (1) | BR112013013525A2 (pt-pt) |
CA (1) | CA2817654A1 (pt-pt) |
EA (1) | EA029180B1 (pt-pt) |
IL (1) | IL226231B (pt-pt) |
MX (1) | MX2013005974A (pt-pt) |
NZ (1) | NZ610701A (pt-pt) |
WO (2) | WO2012072256A2 (pt-pt) |
ZA (1) | ZA201303289B (pt-pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
AU2007260207B2 (en) | 2006-06-15 | 2012-11-08 | Ucb Pharma Gmbh | Pharmaceutical composition with synergistic anticonvulsant effect |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
EP2529731A1 (en) * | 2011-06-01 | 2012-12-05 | Nitto Denko Corporation | Particulate preparation and method for producing the same |
US8779355B2 (en) | 2011-12-28 | 2014-07-15 | Quest Diagnostics Investments, Inc. | Methods for detecting lacosamide by mass spectrometry |
KR101732731B1 (ko) | 2013-04-02 | 2017-05-08 | 주식회사 바이오파마티스 | 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 |
WO2014180895A1 (en) * | 2013-05-08 | 2014-11-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of lacosamide |
EP3074004A2 (en) * | 2013-11-29 | 2016-10-05 | UCB Pharma GmbH | Pharmaceutical composition comprising lacosamide and levetiracetam |
EP2878296A1 (en) | 2013-11-29 | 2015-06-03 | UCB Pharma GmbH | Pharmaceutical composition comprising lacosamide and levetiracetam |
WO2015175982A1 (en) * | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally administrable formulations for the controlled release of a pharmacologically active agent |
WO2016131947A1 (en) | 2015-02-20 | 2016-08-25 | Ucb Biopharma Sprl | Combination treatment |
JO3543B1 (ar) * | 2015-09-28 | 2020-07-05 | Applied Pharma Res | تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم |
CA3008170A1 (en) | 2015-12-30 | 2017-07-06 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
WO2018062955A1 (ko) * | 2016-09-29 | 2018-04-05 | 에스케이케미칼(주) | 라코사미드 서방성 제제 |
CN106551900A (zh) * | 2016-12-05 | 2017-04-05 | 北京万全德众医药生物技术有限公司 | 一种拉科酰胺口服溶液及其制备工艺 |
HRP20240106T1 (hr) * | 2016-12-09 | 2024-04-12 | Alexza Pharmaceuticals, Inc. | Alprazolam za uporabu u liječenju epilepsije |
KR102083241B1 (ko) | 2018-02-14 | 2020-03-02 | 환인제약 주식회사 | 라코사미드를 함유하는 약제학적 서방성 조성물 |
CN110833528A (zh) * | 2018-08-17 | 2020-02-25 | 北京万全德众医药生物技术有限公司 | 一种拉科酰胺脂质体冻干粉针剂及其制备方法 |
CN109010301B (zh) * | 2018-09-05 | 2021-01-26 | 上海上药第一生化药业有限公司 | 一种拉考沙胺晶型ii片剂及其制备方法和应用 |
CN114404393B (zh) * | 2019-06-06 | 2023-02-24 | 上海奥科达生物医药科技有限公司 | 一种拉考沙胺药物组合物及其药物制剂 |
CN112022804A (zh) * | 2020-09-28 | 2020-12-04 | 健民药业集团股份有限公司 | 一种拉考沙胺口服溶液及制备方法 |
WO2022194198A1 (zh) * | 2021-03-17 | 2022-09-22 | 上海博志研新药物技术有限公司 | 一种拉考沙胺药物组合物、其制备方法及应用 |
WO2024054987A1 (en) * | 2022-09-08 | 2024-03-14 | The Children's Hospital Of Philadlphia | Gpcr latrophilin-3 as biomarker for detecting increased risk for mild brain injury and methods of use thereof for diagnosis and treatment of the same |
CN115581676A (zh) * | 2022-09-30 | 2023-01-10 | 澳美制药(苏州)有限公司 | 拉考沙胺片剂及其制备工艺 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69705210T2 (de) | 1996-03-15 | 2001-09-20 | Res Corp Technologies Inc | Krampflösende, enantiomere aminosäure-derivate |
ES2184300T3 (es) | 1997-07-15 | 2003-04-01 | Res Corp Technologies Inc | Derivados de aminoacidos utiles para tratar el accidente vascular encefalico. |
EP1243262B1 (en) | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
PT1243263E (pt) | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
DE602004020657D1 (de) | 2003-12-02 | 2009-05-28 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen |
US20060009384A1 (en) | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
EP1541138A1 (en) | 2003-12-05 | 2005-06-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating status epilepticus or related conditions |
US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
EP1579858A1 (en) | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
EP1604654A1 (en) | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
US7427601B2 (en) | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
NZ552651A (en) | 2004-08-27 | 2010-07-30 | Sanol Arznei Schwarz Gmbh | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
JP2006124385A (ja) * | 2004-09-30 | 2006-05-18 | Takeda Chem Ind Ltd | 放出制御製剤 |
US20060105663A1 (en) * | 2004-10-04 | 2006-05-18 | Stefan Greulich | Polymer assemblies with decorative surfaces |
ES2294979T1 (es) * | 2005-01-27 | 2008-04-16 | Alembic Limited | Formulacion de levetiracetam de liberacion prolongada. |
EA015566B1 (ru) | 2005-01-28 | 2011-10-31 | ЮСиБи ФАРМА ГМБХ | Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая |
JP5371427B2 (ja) * | 2005-07-07 | 2013-12-18 | ファーナム・カンパニーズ・インコーポレーテッド | 高水溶性薬剤用徐放性医薬組成物 |
EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
WO2007120485A2 (en) * | 2006-03-30 | 2007-10-25 | Cinergen, Llc | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor |
EP1873527A1 (en) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
AU2007260207B2 (en) | 2006-06-15 | 2012-11-08 | Ucb Pharma Gmbh | Pharmaceutical composition with synergistic anticonvulsant effect |
CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EP1920780A1 (en) | 2006-10-12 | 2008-05-14 | Schwarz Pharma Ag | Peptide compounds for the treatment of hyperexcitability disorders |
EP1925314A1 (en) | 2006-11-22 | 2008-05-28 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
ES2365574T3 (es) * | 2007-01-11 | 2011-10-07 | Xenoport, Inc. | Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento. |
WO2009069089A1 (en) | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Levetiracetam controlled release composition |
US20090143362A1 (en) | 2007-12-04 | 2009-06-04 | Barabde Umesh Vinayakrao | Carbamazepine formulations |
DE102008059155A1 (de) * | 2008-11-27 | 2010-06-02 | Ratiopharm Gmbh | Trockenverarbeitung und neue Formen von Lacosamid |
KR100980999B1 (ko) * | 2008-11-28 | 2010-09-07 | 기아자동차주식회사 | 차량용 시거라이터조립체 |
WO2010148300A1 (en) | 2009-06-19 | 2010-12-23 | The University Of North Carolina At Chapel Hill | Methods of treatment of neurological disorders |
EP2509939A4 (en) | 2009-09-23 | 2013-09-18 | Univ North Carolina | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2- (ACYLAMIDO) ACETIC ACID AND 2- (ACYLAMIDO) PROPIONIC ACIDS: POWERFUL NEUROLOGIC AGENTS |
EP2496220B1 (en) * | 2009-11-03 | 2019-10-16 | Lupin Limited | Modified release formulation of lacosamide |
WO2011101863A2 (en) * | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
-
2011
- 2011-12-01 AU AU2011335415A patent/AU2011335415B2/en not_active Ceased
- 2011-12-01 EP EP11791442.4A patent/EP2645997B1/en active Active
- 2011-12-01 MX MX2013005974A patent/MX2013005974A/es not_active Application Discontinuation
- 2011-12-01 WO PCT/EP2011/006027 patent/WO2012072256A2/en active Application Filing
- 2011-12-01 JP JP2013541248A patent/JP6027539B2/ja active Active
- 2011-12-01 CA CA 2817654 patent/CA2817654A1/en not_active Abandoned
- 2011-12-01 EA EA201390804A patent/EA029180B1/ru not_active IP Right Cessation
- 2011-12-01 EP EP11817472.1A patent/EP2646001A2/en not_active Withdrawn
- 2011-12-01 WO PCT/EP2011/006026 patent/WO2012084126A2/en active Application Filing
- 2011-12-01 US US13/990,863 patent/US20130251813A1/en not_active Abandoned
- 2011-12-01 NZ NZ610701A patent/NZ610701A/en not_active IP Right Cessation
- 2011-12-01 CN CN201180057820.9A patent/CN103561727B/zh not_active Expired - Fee Related
- 2011-12-01 BR BR112013013525A patent/BR112013013525A2/pt not_active Application Discontinuation
- 2011-12-01 EP EP20188230.5A patent/EP3766485A1/en not_active Withdrawn
-
2012
- 2012-02-01 KR KR1020137017171A patent/KR101980386B1/ko active IP Right Grant
-
2013
- 2013-05-07 ZA ZA2013/03289A patent/ZA201303289B/en unknown
- 2013-05-08 IL IL226231A patent/IL226231B/en active IP Right Grant
-
2014
- 2014-10-21 US US14/519,338 patent/US20150104507A1/en not_active Abandoned
-
2016
- 2016-10-14 JP JP2016202383A patent/JP6357687B2/ja active Active
-
2018
- 2018-07-05 US US16/027,963 patent/US20190008758A1/en not_active Abandoned
- 2018-08-21 US US16/106,655 patent/US20190054009A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA029180B1 (ru) | 2018-02-28 |
KR101980386B1 (ko) | 2019-05-20 |
AU2011335415A1 (en) | 2013-06-20 |
EP2646001A2 (en) | 2013-10-09 |
ZA201303289B (en) | 2014-02-26 |
JP2017031206A (ja) | 2017-02-09 |
US20190054009A1 (en) | 2019-02-21 |
EP2645997A2 (en) | 2013-10-09 |
CN103561727A (zh) | 2014-02-05 |
US20130251813A1 (en) | 2013-09-26 |
JP2013545762A (ja) | 2013-12-26 |
IL226231A0 (en) | 2013-07-31 |
BR112013013525A2 (pt) | 2016-10-18 |
WO2012072256A3 (en) | 2014-01-23 |
AU2011335415B2 (en) | 2016-05-19 |
JP6027539B2 (ja) | 2016-11-16 |
KR20150034579A (ko) | 2015-04-03 |
EA201390804A1 (ru) | 2013-10-30 |
WO2012084126A2 (en) | 2012-06-28 |
MX2013005974A (es) | 2013-07-29 |
NZ610701A (en) | 2015-06-26 |
CA2817654A1 (en) | 2012-06-07 |
JP6357687B2 (ja) | 2018-07-18 |
EP2645997B1 (en) | 2022-08-10 |
US20190008758A1 (en) | 2019-01-10 |
WO2012072256A2 (en) | 2012-06-07 |
IL226231B (en) | 2018-01-31 |
US20150104507A1 (en) | 2015-04-16 |
WO2012084126A3 (en) | 2013-05-02 |
EP3766485A1 (en) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103561727B (zh) | 每日给药1次的拉科酰胺制剂 | |
US6458384B2 (en) | Pharmaceutical with predetermined activity profile | |
DE60221691T3 (de) | Tamsulosin tabletten ohne nahrungsmitteleffekt | |
CN105025886B (zh) | 地拉罗司(deferasirox)的口服制剂 | |
CN107666914A (zh) | 帕博西尼的固体剂型 | |
EP3263117A1 (en) | Oral therapeutic compound delivery system | |
CN109223724A (zh) | 柠檬酸铁剂型 | |
TWI285116B (en) | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients | |
WO2002030400A1 (fr) | Preparations solides | |
CN101795673A (zh) | 增强的拉莫三嗪制剂 | |
CN101166543A (zh) | 含抗痴呆药物的组合物 | |
CN101069675A (zh) | 用于减轻痉挛状态的体征和症状的方法 | |
JP5687185B2 (ja) | 多粒子系を含む二段階の放出プロフィールを有する固形経口剤 | |
WO2014157137A1 (ja) | シロドシンの苦味をマスキングした経口投与製剤 | |
US20230240999A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
EP2036546B1 (en) | Psychostimulant containing pharmaceutical composition | |
JP2021530572A (ja) | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 | |
JP2003516347A (ja) | 時間療法用ジルチアゼム製剤およびその投与法 | |
WO2016051782A1 (ja) | 苦味を有する薬剤の苦味をマスキングした経口投与製剤 | |
BR112020021812A2 (pt) | forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem | |
CN103316026A (zh) | 含芬特明和托吡酯的联合产品及其制备方法 | |
DE69914360T2 (de) | Chromone zubereitung zur enteralen wirkstofffreisetzung | |
CN107998092B (zh) | 药物缓释单元、包含该药物缓释单元的口腔崩解缓释片及其制备方法和用途 | |
JP2000119190A (ja) | 漢方含有錠剤および漢方充填カプセル剤および生薬含有錠剤および生薬充填カプセル剤および漢方含有錠剤の製造方法および漢方充填カプセル剤の製造方法および生薬含有錠剤の製造方法および生薬充填カプセル剤の製造方法 | |
JP2023503056A (ja) | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180327 Termination date: 20201201 |